Musaffa Logo

Our certifications

Independent proof that every stock and portfolio meets halal standards.

How we screen every stock
METHODOLOGY

How we screen every stock

Our 5-step halal methodology, in 90 seconds.

SNSE Shariah Compliance

Screening Methodology: AAOIFI

NOT HALAL

Last Updated: June 15, 2026

Report Source: 2026 1st Quarter Report

Analyst's Ratings for Sensei Biotherapeutics Inc (SNSE)

Based on 6 analysts giving stock ratings to Sensei Biotherapeutics Inc in the past 3 months

Strong
Sell
SellHoldBuyStrong
Buy
Strong Buy
0
Buy
0
Hold
50
Sell
17
Strong Sell
33
Sensei Biotherapeutics Inc

Sensei Biotherapeutics Inc. Stock Analysis SNSE

United States Health Care Nano Cap Report:
Sensei Biotherapeutics, Inc. is a clinical-stage biopharmaceutical company which focuses on the discovery, development, and delivery of next generation immunotherapies for the treatment of cancer and infectious diseases. The company is headquartered in Rockville, Maryland and currently employs 29 full-time employees. The company went IPO on 2021-02-04. The firm's lead program is PIKTOR, an investigational multi-node inhibitor of the PI3K/AKT/mTOR pathway in development for endometrial and breast cancer. The firm is also completing a Phase I/II trial of solnerstotug, its V-domain Ig suppressor of T cell activation (VISTA) inhibitor, in patients with advanced solid tumors. Its TMAb platform is designed to enable highly selective targeting through conditional antibody activation of immune cells in the tumor microenvironment without on-target, off-tumor activity. Its programs include Solnerstotug (SNS-101), SNS-102, SNS-103, and SNS-201. Solnerstotug is a conditionally active, human monoclonal IgG1 antibody designed to block the VISTA checkpoint, which acts as a suppressor of T cells by binding the receptor PSGL-1.
Read More

Sensei Biotherapeutics Inc (SNSE) Chart

Key Statistics of Sensei Biotherapeutics Inc (SNSE)

Key statistics in the stock market are essential financial indicators that measure a company's performance, valuation, profitability, and risk.

Today's Range

$13.76$16.52

Today's Open

$15.21

Volume

140.07K

P/E Ratio (TTM)

-

52 Week Range

$5.60$36.76

Market Cap

23.55M

Avg. Volume

59.86K

Dividend Yield

-

Financial Metrics & Statements of Sensei Biotherapeutics Inc (SNSE)

FAQ's for Sensei Biotherapeutics Inc (SNSE)

  • According to Musaffa’s Shariah screening methodology, Sensei Biotherapeutics Inc (SNSE) is currently classified as NOT HALAL as of June 2026. The classification is based on an evaluation of the company’s business activities and financial ratios to determine whether it meets Islamic investment guidelines.
  • A stock is Shariah-compliant if the company operates in permissible business activities and meets Islamic financial screening thresholds. Musaffa analyzes Sensei Biotherapeutics Inc using these criteria to determine its compliance status.
  • Muslim investors may consider investing in Sensei Biotherapeutics Inc if it meets Shariah compliance standards. Investors typically review the company’s business activities, debt levels, and non-permissible income before making a decision.
  • Musaffa determines the Shariah status of Sensei Biotherapeutics Inc by analyzing whether the company’s core business operations are permissible and whether its financial ratios fall within accepted Islamic thresholds.
  • The Shariah compliance status of Sensei Biotherapeutics Inc may be updated periodically when new financial statements, earnings reports, or business activity information become available.
  • Yes. A stock that is currently Shariah-compliant may become non-compliant if the company’s financial ratios exceed Shariah thresholds or its business activities change.
  • You can check the latest Shariah compliance status of Sensei Biotherapeutics Inc on Musaffa’s stock page, where screening results and key financial indicators are updated to help Muslim investors make informed decisions.

Disclaimer

The content provided on this website is intended solely for informational and educational purposes. Musaffa is a technology, data, education, and research company. We are not licensed financial service provider by the authorized relevant financial service regulator in India or any other regulatory government body, and we do not offer or facilitate any trading, brokerage, investment, or financial advisory services. We do not deliberately target an audience seeking financial services.

By accessing this website, you acknowledge and confirm that you are seeking information relating to Musaffa of your own accord, and that there has been no form of solicitation, advertisement, or inducement by Musaffa or its members. Musaffa shall not be liable for the consequences of any action taken by relying on the material or information provided on this website. The contents of this website are the intellectual property of Musaffa.